Cann Group Valuation
Is CAN undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Key Valuation Metric
Which metric is best to use when looking at relative valuation for CAN?
Other financial metrics that can be useful for relative valuation.
| What is CAN's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | AU$54.39m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 7.3x |
| Enterprise Value/EBITDA | -4.5x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does CAN's PS Ratio compare to its peers?
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 30.3x | ||
ANP Antisense Therapeutics | 29x | -27.1% | AU$56.2m |
FRE Firebrick Pharma | 30.7x | n/a | AU$32.1m |
EMD Emyria | 29.6x | n/a | AU$49.6m |
RCE Recce Pharmaceuticals | 32.1x | 31.2% | AU$98.0m |
CAN Cann Group | 3.9x | n/a | AU$54.4m |
Price to Earnings Ratio vs Industry
How does CAN's PE Ratio compare vs other companies in the AU Pharmaceuticals Industry?
Price to Sales Ratio vs Fair Ratio
What is CAN's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 3.9x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate CAN's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of CAN when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?